Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
Type:
Grant
Filed:
September 19, 2008
Date of Patent:
January 28, 2014
Assignees:
Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite de Versailles—St Quentin en Yvelines, Universite Paris—SUD
Inventors:
William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall